$ELTP
ELITE PHARMACEUTICALS INC /NV/ Stock $eltp

$eltp Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-Q Financial Statement

#000149315223028434 Filed on August 14, 2023

Income Statement

Concept	2023 Q3	2023 Q2
Revenue	$14.16M	$9.000M
YoY Change	64.89%	17.3%
Cost Of Revenue	$7.710M	$4.230M
YoY Change	61.93%	15.09%
Gross Profit	$6.447M	$4.751M
YoY Change	68.58%	18.83%
Gross Profit Margin	45.54%	52.78%
Selling, General & Admin	$1.576M	$1.677M
YoY Change	31.72%	-2.71%
% of Gross Profit	24.45%	35.29%
Research & Development	$2.618M	$1.144M
YoY Change	113.35%	19.69%
% of Gross Profit	40.61%	24.07%
Depreciation & Amortization	$327.2K	$328.3K
YoY Change	3.55%	10.8%
% of Gross Profit	5.08%	6.91%
Operating Expenses	$4.522M	$3.149M
YoY Change	64.82%	5.83%
Operating Profit	$1.926M	$1.602M
YoY Change	78.1%	56.65%
Interest Expense	$130.4K	$119.4K
YoY Change	-46.27%	-44.92%
% of Operating Profit	6.77%	7.45%
Other Income/Expense, Net	-$4.658M	-$305.3K
YoY Change	-1145.38%	-57.41%
Pretax Income	-$2.733M	$1.297M
YoY Change	-279.0%	323.94%
Income Tax	-$17.70M	$155.0K
% Of Pretax Income		11.95%
Net Earnings	$14.93M	$1.142M
YoY Change	885.69%	273.28%
Net Earnings / Revenue	105.49%	12.69%
Basic Earnings Per Share	$0.01	$0.00
Diluted Earnings Per Share	$0.01	$0.00
COMMON SHARES
Basic Shares Outstanding	1.014B shares	1.014B shares
Diluted Shares Outstanding	1.019B shares	1.015B shares

Balance Sheet

Concept	2023 Q3	2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$8.654M	$9.077M
YoY Change	-53.36%	-54.11%
Cash & Equivalents	$8.654M	$9.077M
Short-Term Investments
Other Short-Term Assets	$355.6K	$998.1K
YoY Change	61.73%	96.5%
Inventory	$15.22M	$11.17M
Prepaid Expenses
Receivables	$10.50M	$6.201M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$34.73M	$27.44M
YoY Change	13.97%	-13.89%
LONG-TERM ASSETS
Property, Plant & Equipment	$9.770M	$10.10M
YoY Change	-7.34%	75.47%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$21.02K	$21.02K
YoY Change	-77.09%	-92.79%
Other Assets	$19.86M	$2.587M
YoY Change	670.51%	0.4%
Total Long-Term Assets	$35.99M	$19.05M
YoY Change	81.12%	17.34%
TOTAL ASSETS
Total Short-Term Assets	$34.73M	$27.44M
Total Long-Term Assets	$35.99M	$19.05M
Total Assets	$70.72M	$46.50M
YoY Change	40.47%	-3.34%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.609M	$1.875M
YoY Change	109.39%	16.15%
Accrued Expenses	$11.16M	$5.929M
YoY Change	143.71%	23.28%
Deferred Revenue	$13.33K	$13.33K
YoY Change	0.0%	0.0%
Short-Term Debt	$4.000M	$4.000M
YoY Change
Long-Term Debt Due	$295.2K	$251.3K
YoY Change	-41.28%	-42.23%
Total Short-Term Liabilities	$19.08M	$12.08M
YoY Change	178.79%	70.59%
LONG-TERM LIABILITIES
Long-Term Debt	$3.355M	$3.578M
YoY Change	-78.4%	-72.91%
Other Long-Term Liabilities	$3.192M	$726.6K
YoY Change		1691.89%
Total Long-Term Liabilities	$6.547M	$4.305M
YoY Change	-59.86%	-72.22%
TOTAL LIABILITIES
Total Short-Term Liabilities	$19.08M	$12.08M
Total Long-Term Liabilities	$6.547M	$4.305M
Total Liabilities	$25.62M	$16.38M
YoY Change	10.68%	-27.43%
SHAREHOLDERS EQUITY
Retained Earnings	-$120.4M	-$135.4M
YoY Change	-12.89%	-3.15%
Common Stock	$1.014M	$1.014M
YoY Change	0.0%	0.26%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$306.8K	$306.8K
YoY Change	0.0%	0.0%
Treasury Stock Shares
Shareholders Equity	$45.09M	$30.12M
YoY Change
Total Liabilities & Shareholders Equity	$70.72M	$46.50M
YoY Change	40.47%	-3.34%

Cashflow Statement

Concept	2023 Q3	2023 Q2
OPERATING ACTIVITIES
Net Income	$14.93M	$1.142M
YoY Change	885.69%	273.28%
Depreciation, Depletion And Amortization	$327.2K	$328.3K
YoY Change	3.55%	10.8%
Cash From Operating Activities	-$235.9K	-$2.710M
YoY Change	-115.78%	386.05%
INVESTING ACTIVITIES
Capital Expenditures	$0.00
YoY Change	-100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	$0.00
YoY Change	-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-179.5K	$3.957M
YoY Change	-107.53%	-66.74%
NET CHANGE
Cash From Operating Activities	-235.9K	-$2.710M
Cash From Investing Activities	0.000
Cash From Financing Activities	-179.5K	$3.957M
Net Change In Cash	-415.4K	$1.247M
YoY Change	-66.08%	-88.91%
FREE CASH FLOW
Cash From Operating Activities	-$235.9K	-$2.710M
Capital Expenditures	$0.00
Free Cash Flow	-$235.9K	-$2.710M
YoY Change	-103.57%	485.38%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q2	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther		usd
CY2023Q2	dei	Entity Central Index Key EntityCentralIndexKey	0001053369
CY2023Q2	dei	Amendment Flag AmendmentFlag	false
CY2023Q2	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q2	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--03-31
CY2023Q2	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2023Q1	us-gaap	Other Loans Payable OtherLoansPayable		usd
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022Q2	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts		usd
CY2023Q2	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
CY2023Q2	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
CY2023Q2	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable		usd
CY2022Q2	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt		usd
CY2022Q2	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2023Q2	ELTP	Finitelived Intangible Assets Impairment FinitelivedIntangibleAssetsImpairment		usd
CY2023Q2	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther		usd
CY2022Q2	us-gaap	Dilutive Securities DilutiveSecurities		usd
CY2023Q1	us-gaap	Litigation Reserve Current LitigationReserveCurrent		usd
CY2023Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent		usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2023Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1		usd
CY2023Q2	dei	Document Type DocumentType	10-Q
CY2023Q2	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q2	dei	Document Period End Date DocumentPeriodEndDate	2023-06-30
CY2023Q2	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q2	dei	Entity File Number EntityFileNumber	001-15697
CY2023Q2	dei	Entity Registrant Name EntityRegistrantName	ELITE PHARMACEUTICALS, INC.
CY2023Q2	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2023Q2	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	22-3542636
CY2023Q2	dei	Entity Address Address Line1 EntityAddressAddressLine1	165 LUDLOW AVENUE
CY2023Q2	dei	Entity Address City Or Town EntityAddressCityOrTown	NORTHVALE
CY2023Q2	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
CY2023Q2	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	07647
CY2023Q2	dei	City Area Code CityAreaCode	(201) 750-2646
CY2023Q2	dei	Local Phone Number LocalPhoneNumber	750-2646
CY2023Q2	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2023Q2	dei	Trading Symbol TradingSymbol	ELTP
CY2023Q2	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q2	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q2	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q2	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q2	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q2	dei	Entity Shell Company EntityShellCompany	false
CY2023Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	1013915081	shares
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9076659	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7832247	usd
CY2023Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	100000	usd
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	usd
CY2023Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	6201448	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3094549	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	11168431	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	9550716	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	998058	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1032785	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	27444596	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	21510297	usd
CY2023Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	14914617	usd
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	14586335	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10097876	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10426158	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	6341228	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	6341228	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7528	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	13062	usd
CY2023Q2	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	2171821	usd
CY2023Q1	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	2171821	usd
CY2023Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	415430	usd
CY2023Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	412434	usd
CY2023Q2	us-gaap	Security Deposit SecurityDeposit	21018	usd
CY2023Q1	us-gaap	Security Deposit SecurityDeposit	21018	usd
CY2023Q2	us-gaap	Other Assets OtherAssets	436448	usd
CY2023Q1	us-gaap	Other Assets OtherAssets	433452	usd
CY2023Q2	us-gaap	Assets Assets	46499497	usd
CY2023Q1	us-gaap	Assets Assets	40896018	usd
CY2023Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1874925	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	2446810	usd
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5929353	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5047726	usd
CY2023Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	13333	usd
CY2023Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	13333	usd
CY2023Q2	us-gaap	Secured Debt Current SecuredDebtCurrent	110822	usd
CY2023Q1	us-gaap	Secured Debt Current SecuredDebtCurrent	110822	usd
CY2023Q2	us-gaap	Loans Payable Current LoansPayableCurrent	140454	usd
CY2023Q1	us-gaap	Loans Payable Current LoansPayableCurrent	200032	usd
CY2023Q2	us-gaap	Other Loans Payable OtherLoansPayable	4000000	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	8586	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	14914	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	12077473	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	7833637	usd
CY2023Q2	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	15556	usd
CY2023Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	18890	usd
CY2023Q2	us-gaap	Secured Long Term Debt SecuredLongTermDebt	1032568	usd
CY2023Q1	us-gaap	Secured Long Term Debt SecuredLongTermDebt	1029018	usd
CY2023Q2	us-gaap	Long Term Loans Payable LongTermLoansPayable	2545753	usd
CY2023Q1	us-gaap	Long Term Loans Payable LongTermLoansPayable	2532502	usd
CY2023Q2	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	711078	usd
CY2023Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	521711	usd
CY2023Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	4304955	usd
CY2023Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	4102121	usd
CY2023Q2	us-gaap	Liabilities Liabilities	16382428	usd
CY2023Q1	us-gaap	Liabilities Liabilities	11935758	usd
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1445000000	shares
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1445000000	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1014015081	shares
CY2023Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-305263	usd
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-716801	usd
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1013915081	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1014015081	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1013915081	shares
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	1014019	usd
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	1014019	usd
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	164765980	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	164750980	usd
CY2023Q2	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	100000	shares
CY2023Q1	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	100000	shares
CY2023Q2	us-gaap	Treasury Stock Value TreasuryStockValue	306841	usd
CY2023Q1	us-gaap	Treasury Stock Value TreasuryStockValue	306841	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-135356089	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-136497898	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	30117069	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	28960260	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	46499497	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	40896018	usd
CY2023Q2	ELTP	Revenue From Manufacturing Fees RevenueFromManufacturingFees	7909237	usd
CY2022Q2	ELTP	Revenue From Manufacturing Fees RevenueFromManufacturingFees	6327141	usd
CY2023Q2	ELTP	Revenue From Licensing Fees RevenueFromLicensingFees	1070839	usd
CY2022Q2	ELTP	Revenue From Licensing Fees RevenueFromLicensingFees	1345767	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	8980076	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7672908	usd
CY2023Q2	us-gaap	Cost Of Revenue CostOfRevenue	4229521	usd
CY2022Q2	us-gaap	Cost Of Revenue CostOfRevenue	3675061	usd
CY2023Q2	us-gaap	Gross Profit GrossProfit	4750555	usd
CY2022Q2	us-gaap	Gross Profit GrossProfit	3997847	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1143545	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	955443	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1661704	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1718104	usd
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	15000	usd
CY2022Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5322	usd
CY2023Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	328282	usd
CY2022Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	296294	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	3148531	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	2975163	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	1602024	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	1022684	usd
CY2023Q2	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-189367	usd
CY2022Q2	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-500143	usd
CY2023Q2	us-gaap	Interest Expense InterestExpense	119412	usd
CY2022Q2	us-gaap	Interest Expense InterestExpense	216787	usd
CY2023Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	3516	usd
CY2022Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	129	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	1296761	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	305883	usd
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	154952	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	1141809	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	305883	usd
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.00
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.00
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.00
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.00
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1013915081	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1011381988	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1014572821	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1011381988	shares
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	28960260	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	1141809	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	15000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	30117069	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	25222027	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	305883	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5322	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	25533232	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	1141809	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	305883	usd
CY2023Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	328282	usd
CY2022Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	296294	usd
CY2023Q2	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	100000	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	5534	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	51013	usd
CY2023Q2	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-189367	usd
CY2022Q2	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-500143	usd
CY2023Q2	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	15000	usd
CY2022Q2	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	5322	usd
CY2023Q2	ELTP	Noncash Rent Expense And Lease Accretion NoncashRentExpenseAndLeaseAccretion	192	usd
CY2022Q2	ELTP	Noncash Rent Expense And Lease Accretion NoncashRentExpenseAndLeaseAccretion	602	usd
CY2023Q2	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3206899	usd
CY2022Q2	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	907196	usd
CY2023Q2	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1617715	usd
CY2022Q2	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	875993	usd
CY2023Q2	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-34727	usd
CY2022Q2	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	180974	usd
CY2023Q2	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	309550	usd
CY2022Q2	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	299968	usd
CY2023Q2	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-3334	usd
CY2022Q2	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-3337	usd
CY2023Q2	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-6328	usd
CY2022Q2	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-49241	usd
CY2023Q2	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2709815	usd
CY2022Q2	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-557516	usd
CY2022Q2	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	94597	usd
CY2022Q2	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-94597	usd
CY2022Q2	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	12000000	usd
CY2023Q2	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	4000000	usd
CY2023Q2	us-gaap	Payments Of Loan Costs PaymentsOfLoanCosts	42777	usd
CY2022Q2	us-gaap	Payments Of Loan Costs PaymentsOfLoanCosts	103536	usd
CY2023Q2	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3957223	usd
CY2022Q2	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	11896464	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	1247408	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	11244351	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	8244681	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	8940396	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	9492089	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	20184747	usd
CY2023Q2	us-gaap	Interest Paid Net InterestPaidNet	119412	usd
CY2022Q2	us-gaap	Interest Paid Net InterestPaidNet	216787	usd
CY2023Q2	us-gaap	Income Taxes Paid IncomeTaxesPaid	127522	usd
CY2023Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	1141809	usd
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	305883	usd
CY2023Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	1141809	usd
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	305883	usd
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1013915081	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1011381988	shares
CY2023Q2	us-gaap	Dilutive Securities DilutiveSecurities	657740	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	8980076	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7672908	usd
CY2023Q2	us-gaap	Restricted Cash RestrictedCash	415430	usd
CY2023Q1	us-gaap	Restricted Cash RestrictedCash	412434	usd
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1014572821	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1011381988	shares
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.00
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.00
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.00
CY2023	us-gaap	Exploration Abandonment And Impairment Expense ExplorationAbandonmentAndImpairmentExpense	292807	usd
	us-gaap	Exploration Abandonment And Impairment Expense ExplorationAbandonmentAndImpairmentExpense	0	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	6341228	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	0	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	6341228	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	6634035	usd
CY2023	ELTP	Finitelived Intangible Assets Impairment FinitelivedIntangibleAssetsImpairment	-292807	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	0	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	6341228	usd
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.00
CY2023Q2	us-gaap	Income Tax Examination Likelihood Of Unfavorable Settlement IncomeTaxExaminationLikelihoodOfUnfavorableSettlement	These tax benefits are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate resolution
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	1000000	usd
CY2023Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	521711	usd
CY2023Q2	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-189367	usd
CY2023Q2	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	711078	usd
CY2022Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	936837	usd
CY2022Q2	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-500143	usd
CY2022Q2	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	1436980	usd
CY2023Q2	ELTP	Average Customer Payment Percentage AverageCustomerPaymentPercentage	0.9996	pure
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	9000000.0	usd
CY2023Q2	ELTP	Estimated Allowance EstimatedAllowance	100000	usd
CY2023Q2	ELTP	Revenue Of Percent RevenueOfPercent	0.012	pure
CY2023Q2	srt	Financing Receivable Before Allowance For Credit Loss To Total Percent FinancingReceivableBeforeAllowanceForCreditLossToTotalPercent	0.012	pure
CY2023Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	7808657	usd
CY2023Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	2352330	usd
CY2023Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	90922	usd
CY2023Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	1791311	usd
CY2023Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	3268852	usd
CY2023Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	5407075	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	11168431	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	9550716	usd
CY2023Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	25012493	usd
CY2023Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	25012493	usd
CY2023Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	14914617	usd
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	14586335	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10097876	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10426158	usd
CY2023Q2	us-gaap	Depreciation Depreciation	328282	usd
CY2022Q2	us-gaap	Depreciation Depreciation	292748	usd
CY2023Q2	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	4470001	usd
CY2023Q1	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	4125000	usd
CY2023Q2	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	564985	usd
CY2023Q1	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	414989	usd
CY2023Q2	ELTP	Accrued Consultant Contract Fees AccruedConsultantContractFees	193333	usd
CY2023Q1	ELTP	Accrued Consultant Contract Fees AccruedConsultantContractFees	193333	usd
CY2023Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	125000	usd
CY2023Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	125000	usd
CY2023Q2	ELTP	Accrued Director Dues AccruedDirectorDues	107500	usd
CY2023Q1	ELTP	Accrued Director Dues AccruedDirectorDues	70000	usd
CY2023Q2	us-gaap	Litigation Reserve Current LitigationReserveCurrent	90000	usd
CY2023Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	30000	usd
CY2023Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	348534	usd
CY2023Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	119404	usd
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5929353	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5047726	usd
CY2023Q2	us-gaap	Interest Expense Debt InterestExpenseDebt	77238	usd
CY2022Q2	us-gaap	Interest Expense Debt InterestExpenseDebt	177579	usd
CY2023Q2	us-gaap	Deferred Revenue DeferredRevenue	28889	usd
CY2023Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	13333	usd
CY2023Q2	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	15556	usd
CY2023Q1	us-gaap	Deferred Revenue DeferredRevenue	32223	usd
CY2023Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	13333	usd
CY2023Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	18890	usd
CY2020Q4	ELTP	Operating Lease Renewal Term OperatingLeaseRenewalTerm	The Pompano Office has a term of three years, ending on October 31, 2023.
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7528	usd
CY2023Q2	ELTP	Operating Lease Assets OperatingLeaseAssets	7528	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	8586	usd
CY2023Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	8586	usd
CY2022Q2	us-gaap	Payments For Rent PaymentsForRent	58248	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	8694	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	8694	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	108	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	8586	usd
CY2023Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P0Y3M18D
CY2023Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.06	pure
CY2023Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.1521
CY2023Q2	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P3Y9M18D
CY2023Q1	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P4Y1M6D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	15370000	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.07
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y4M24D
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	15370000	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.05
CY2023Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y2M12D
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	4182000	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.08
CY2023Q2	ELTP	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableOutstandingWeightedAverageRemainingContractualTerm	P2Y
CY2023Q2	ELTP	Price Difference Between Exercise Price And Quoted Price PriceDifferenceBetweenExercisePriceAndQuotedPrice	0.04
CY2023Q1	ELTP	Price Difference Between Exercise Price And Quoted Price PriceDifferenceBetweenExercisePriceAndQuotedPrice	0.03
CY2023Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	184722	usd
CY2023Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y3M18D
CY2023Q2	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.115	pure
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	154952	usd
CY2022Q2	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.0000	pure
CY2023Q2	ELTP	Effective Income Tax Rate Reconciliation Valuation Allowance Tax Rate EffectiveIncomeTaxRateReconciliationValuationAllowanceTaxRate	0.21	pure

Files In Submission

Name	View Source	Status
0001493152-23-028434-index-headers.html	Edgar Link	pending
0001493152-23-028434-index.html	Edgar Link	pending
0001493152-23-028434.txt	Edgar Link	pending
0001493152-23-028434-xbrl.zip	Edgar Link	pending
eltp-20230630.xsd	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
eltp-20230630_cal.xml	Edgar Link	unprocessable
eltp-20230630_def.xml	Edgar Link	unprocessable
eltp-20230630_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
eltp-20230630_pre.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ELTP
ELITE PHARMACEUTICALS INC /NV/ Stock $eltp

2023 Q3 Form 10-Q Financial Statement

#000149315223028434 Filed on August 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ELTP ELITE PHARMACEUTICALS INC /NV/ Stock $eltp

2023 Q3 Form 10-Q Financial Statement

#000149315223028434 Filed on August 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ELTP
ELITE PHARMACEUTICALS INC /NV/ Stock $eltp